Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.65 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.58 |
| ▸ | HTT | P42858 | 1/20 | 0.58 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | F2 | P00734 | 3/20 | 0.55 |
| ▸ | PRSS1 | P07477 | 3/20 | 0.55 |
| ▸ | PRSS2 | P07478 | 3/20 | 0.55 |
| ▸ | PRSS3 | P35030 | 3/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | EDNRA | P25101 | 9/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.49 |
| ▸ | NSD2 | O96028 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
| ▸ | EDNRB | P24530 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6046339 | 0.87 | CA2 (0.61) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL7558142 | 0.87 | CA2 (0.61) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL27495668 | 0.82 | CA2 (0.64) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL13588761 | 0.82 | HTR6 (0.56) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL3762979 | 0.81 | CA2 (0.54) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL1268593 | 0.81 | CA2 (0.54) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL9019311 | 0.80 | CA2 (0.71) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL1131010 | 0.80 | CA2 (0.71) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL14176763 | 0.80 | CA2 (0.61) | CA2CYP1A2CYP2C19HTTHIF1A | |
| SCHEMBL22068731 | 0.80 | CA2 (0.60) | CA2CYP1A2CYP2C19HTTHIF1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023191549-A1 | FLUORESCENT PROBE FOR LABELING M1 MACROPHAGES, AND M1 MACROPHAGE MONITORING SYSTEM USING SAME | 기초과학연구원 | 2023-10-05 | — | — | WO | disclosed |
| US-20220411426-A1 | SUBSTRATE SELECTIVE INHIBITORS OF INSULIN-DEGRADING ENZYME (IDE) AND USES THEREOF | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2022-12-29 | — | — | US | disclosed |
| US-20220308043-A1 | FLUORESCENT PROBES FOR IDENTIFICATION AND QUANTIFICATION OF HEPATIC TRANSPORTERS IN VITRO AND IN VIVO | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2022-09-29 | — | — | US | disclosed |
| US-20210379190-A1 | FAP-ACTIVATED PROTEASOME INHIBITORS FOR TREATING SOLID TUMORS | TRUSTEES OF TUFTS COLLEGE | 2021-12-09 | — | — | US | disclosed |
| US-11065339-B2 | FAP-activated proteasome inhibitors for treating solid tumors | TRUSTEES OF TUFTS COLLEGE (US) | 2021-07-20 | — | — | US | disclosed |
| US-11040976-B2 | Substrate selective inhibitors of insulin-degrading enzyme (IDE) and uses thereof | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2021-06-22 | — | — | US | disclosed |
| US-11034991-B2 | Methods to determine KDM1A target engagement and chemoprobes useful therefor | ORYZON GENOMICS S.A. (ES) | 2021-06-15 | — | — | US | disclosed |
| US-20210047329-A1 | SUBSTITUTED 4,6-DIHYDROSPIRO[[1,2,3]TRIAZOLO[4,5-B]PYRIDINE-7,3'-INDOLINE]-2',5(3H)-DIONE ANALOGUES | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2021-02-18 | — | — | US | disclosed |
| US-20200323994-A1 | FAP-ACTIVATED PROTEASOME INHIBITORS FOR TREATING SOLID TUMORS | TRUSTEES OF TUFTS COLLEGE | 2020-10-15 | — | — | US | disclosed |
| WO-2020206979-A1 | SEMI-CONDUCTIVE SHIELDING MATERIAL FOR HIGH VOLTAGE CABLE, AND PREPARATION METHOD AND USE THEREOF | 江苏德威新材料股份有限公司 | 2020-10-15 | — | — | WO | disclosed |
| US-9351491-B2 | Inhibition and dispersion of biofilms in plants with imidazole-triazole derivatives | NORTH CAROLINA STATE UNIVERSITY (US) | 2016-05-31 | — | — | US | disclosed |
| US-9296693-B2 | Acyl piperidine inhibitors of soluble epoxide hydrolase | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2016-03-29 | — | — | US | disclosed |
| US-20140255300-A1 | FAP-Activated Proteasome Inhibitors for Treating Solid Tumors | TRUSTEES OF TUFTS COLLEGE (US) | 2014-09-11 | — | — | US | disclosed |
| US-20130143925-A1 | ACYL PIPERIDINE INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-06-06 | — | — | US | disclosed |
| WO-2013033396-A2 | FAP-ACTIVATED PROTEASOME INHIBITORS FOR TREATING SOLID TUMORS | TRUSTEES OF TUFTS COLLEGE (US) | 2013-03-07 | — | — | WO | disclosed |
| US-8153393-B2 | Spirolactam targeting compounds and related compounds | UNIVERSITY OF MASSACHUSETTS (US) | 2012-04-10 | — | — | US | disclosed |
| US-20110294668-A1 | INHIBITION AND DISPERSION OF BIOFILMS IN PLANTS WITH IMIDAZOLE-TRIAZOLE DERIVATIVES | NORTH CAROLINA STATE UNIVERSITY (US) | 2011-12-01 | — | — | US | disclosed |
| WO-2011089257-A1 | METHOD FOR DETERMINING THE ACTIVITY OF TRANSGLUTAMINASE FACTOR XIIIA | PHILIPPS-UNIVERSITÄT MARBURG (DE) | 2011-07-28 | — | — | WO | disclosed |
| US-20080233609-A1 | Spirolactam Targeting Compounds and Related Compounds | UNIVERSITY OF MASSACHUSETTS | 2008-09-25 | — | — | US | disclosed |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | PHARMACIA CORPORATION | 2007-04-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140255300-A1 | FAP-Activated Proteasome Inhibitors for Treating Solid Tumors | FAP, PSMA1, PSMA6 | CA2 3227/4885CYP1A2 3298/4885CYP2C19 2537/4885 |
| US-20210047329-A1 | SUBSTITUTED 4,6-DIHYDROSPIRO[[1,2,3]TRIAZOLO[4,5-B]PYRIDINE-7,3'-INDOLINE]-2',5(3H)-DIONE ANALOGUES | DHPS, QDPR, HTR5A | CA2 4007/4885CYP1A2 243/4885CYP2C19 1161/4885 |
| US-20210379190-A1 | FAP-ACTIVATED PROTEASOME INHIBITORS FOR TREATING SOLID TUMORS | FAP, PSMA1, PSMA6 | CA2 3227/4885CYP1A2 3298/4885CYP2C19 2537/4885 |
| US-11065339-B2 | FAP-activated proteasome inhibitors for treating solid tumors | FAP, PSMA1, PSMA6 | CA2 3227/4885CYP1A2 3298/4885CYP2C19 2537/4885 |
| US-20110294668-A1 | INHIBITION AND DISPERSION OF BIOFILMS IN PLANTS WITH IMIDAZOLE-TRIAZOLE DERIVATIVES | SOD1, APOBEC3A, CLPP | CA2 1974/4885CYP1A2 939/4885CYP2C19 708/4885 |
| US-20130143925-A1 | ACYL PIPERIDINE INHIBITORS OF SOLUBLE EPOXIDE HYDROLASE | EPHX1, FAAH, FAAH2 | CA2 3835/4885CYP1A2 252/4885CYP2C19 878/4885 |
| US-20080233609-A1 | Spirolactam Targeting Compounds and Related Compounds | AGTR2, AGTR1, REN | CA2 1729/4885CYP1A2 3110/4885CYP2C19 2098/4885 |
| US-20220411426-A1 | SUBSTRATE SELECTIVE INHIBITORS OF INSULIN-DEGRADING ENZYME (IDE) AND USES THEREOF | IDE, SI, GPR119 | CA2 1532/4885CYP1A2 98/4885CYP2C19 44/4885 |
| US-20070078146-A1 | Antiinflamamtory agents; antiarthritic agents; inflammatory bowel disorders; multiple sclerosis; asthma | MAPK1, MAPK3, MAPK4 | CA2 3978/4885CYP1A2 1069/4885CYP2C19 3141/4885 |
| US-11040976-B2 | Substrate selective inhibitors of insulin-degrading enzyme (IDE) and uses thereof | IDE, SI, GPR119 | CA2 1582/4885CYP1A2 106/4885CYP2C19 40/4885 |
| US-20200323994-A1 | FAP-ACTIVATED PROTEASOME INHIBITORS FOR TREATING SOLID TUMORS | FAP, PSMA1, PSMA6 | CA2 3227/4885CYP1A2 3298/4885CYP2C19 2537/4885 |
| US-20220308043-A1 | FLUORESCENT PROBES FOR IDENTIFICATION AND QUANTIFICATION OF HEPATIC TRANSPORTERS IN VITRO AND IN VIVO | ABCB11, SLC10A1, SLC10A2 | CA2 967/4885CYP1A2 669/4885CYP2C19 1830/4885 |
| US-11034991-B2 | Methods to determine KDM1A target engagement and chemoprobes useful therefor | KDM1B, KDM1A, KDM7A | CA2 2841/4885CYP1A2 4170/4885CYP2C19 4815/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.